© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
September 15, 2021
But the good news is treatments can be tailored for patients with the chronic behavioral condition.
September 13, 2021
There are many substances that are included on the prohibited list for the Tokyo Olympics that are considered standard medications for certain disease states.
September 03, 2021
Alterations in the amino acid profile of children with attention-deficit hyperactivity disorder may support further research into potential new treatment strategies.
August 31, 2021
It is currently debated whether or not sluggish cognitive tempo—defined as a collection of symptoms that include persistent dreaminess, fatigue, and slow working speed—is part of ADHD or separate from it.
August 20, 2021
Study indicates that the genetics affecting aggression in children with attention-deficit hyperactivity disorder and disruptive behavior disorders are the same as genetics underlying aggression in the general population.
August 17, 2021
The FDA has approved Qelbree (viloxazine extended-release capsules; Supernus Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 years.
August 16, 2021
The amount of green space surrounding children’s homes may impact the development of ADHD.
August 11, 2021
The strongest associations with attention-deficit hyperactivity disorder were present for nervous system, respiratory, musculoskeletal, and metabolic diseases.
August 09, 2021
Although ADHD is generally treated through medication and/or behavioral treatments, in more than 25% of children, these treatments alone are insufficient.
August 06, 2021
Study suggests attention-deficit hyperactivity disorder medications may lower the risk of suicide in children with hyperactivity, oppositional defiance, and other behavioral disorders.